SG11201807500RA - Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria - Google Patents

Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria

Info

Publication number
SG11201807500RA
SG11201807500RA SG11201807500RA SG11201807500RA SG11201807500RA SG 11201807500R A SG11201807500R A SG 11201807500RA SG 11201807500R A SG11201807500R A SG 11201807500RA SG 11201807500R A SG11201807500R A SG 11201807500RA SG 11201807500R A SG11201807500R A SG 11201807500RA
Authority
SG
Singapore
Prior art keywords
butyric acid
agent
producing bacteria
increasing intestinal
intestinal
Prior art date
Application number
SG11201807500RA
Inventor
Takumi Tochio
Kenta Konishi
Saki Nakamura
Original Assignee
B Food Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Food Science Co Ltd filed Critical B Food Science Co Ltd
Publication of SG11201807500RA publication Critical patent/SG11201807500RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/28—Oligosaccharides
    • A23V2250/284—Oligosaccharides, non digestible

Abstract

[Problem] To provide: an agent for increasing intestinal butyric acid which is capable of effectively increasing intestinal butyric acid; a food composition for increasing intestinal butyric acid; a proliferation agent for butyric acid-producing bacteria; a food composition for proliferating butyric acid-producing bacteria; a method for increasing intestinal butyric acid; a method for proliferating butyric acid-producing bacteria; a method for treating or preventing intestinal inflammation, fatty liver, diabetes, colorectal cancer or obesity using the same; and use of 1-kestose for producing a pharmaceutical preparation for treatment or prevention of these diseases. [Solution] An agent for increasing intestinal butyric acid and a proliferation agent for butyric acid-producing bacteria, each comprising 1-kestose as an active ingredient. According to the present invention, intestinal butyric acid in humans or animals can be easily and effectively increased with little side effects or safety concerns. According to the present invention, furthermore, intestinal inflammation, fatty liver, diabetes, colorectal cancer or obesity can be prevented or treated by increasing intestinal butyric acid in humans or animals.
SG11201807500RA 2016-03-14 2017-03-14 Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria SG11201807500RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016049561 2016-03-14
PCT/JP2017/010066 WO2017159643A1 (en) 2016-03-14 2017-03-14 Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria

Publications (1)

Publication Number Publication Date
SG11201807500RA true SG11201807500RA (en) 2018-09-27

Family

ID=59852313

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807500RA SG11201807500RA (en) 2016-03-14 2017-03-14 Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria

Country Status (8)

Country Link
US (1) US20190091248A1 (en)
EP (1) EP3431089A4 (en)
JP (1) JP6275931B1 (en)
KR (1) KR20180122379A (en)
CN (1) CN109069522A (en)
PH (1) PH12018501988A1 (en)
SG (1) SG11201807500RA (en)
WO (1) WO2017159643A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108064132A (en) 2014-10-31 2018-05-22 霍勒拜欧姆公司 The method and composition related with the antimicrobial treatments of illness and diagnosis
CA3073838A1 (en) 2017-08-30 2019-03-07 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
JP7235270B2 (en) * 2018-02-09 2023-03-08 エースバイオプロダクト株式会社 Blood sugar elevation inhibitor and method for producing same
EP3823651A4 (en) * 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
JP7216260B2 (en) * 2018-11-06 2023-02-01 株式会社明治 Composition for promoting growth of Coprococcus spp.
JP6842072B2 (en) * 2019-03-07 2021-03-17 物産フードサイエンス株式会社 Eggerthella bacteria count suppressant
KR102128287B1 (en) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK19 strain AND uses thereof
KR102128289B1 (en) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 NEW Akkermansia muciniphila EB-AMDK27 strain AND uses thereof
JP2021115000A (en) 2020-01-27 2021-08-10 物産フードサイエンス株式会社 Method of manufacturing solid sugar containing 1-kestose, and solid sugar
CN111820419B (en) * 2020-07-24 2022-05-27 中国海洋大学 Composition for targeted regulation and control of enteron-bacterium and short-chain fatty acid producing bacterium
CN111996267A (en) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 Fluorescent quantitative PCR (polymerase chain reaction) primer group and kit for rapidly detecting AKK (alkyl ketene dimer) bacteria and application of fluorescent quantitative PCR primer group and kit
KR20220097324A (en) * 2020-12-31 2022-07-07 주식회사 삼양사 Growth suppression of gut microbiome using kestose
CN113461751A (en) * 2021-07-15 2021-10-01 量子高科(广东)生物有限公司 Fructooligosaccharide with high kestose content and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004049093A (en) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd Food composition and medicine for increasing intestinal butyric acid
US20050118299A1 (en) * 2003-12-01 2005-06-02 The Iams Company Companion animal compositions comprising short chain oligofructose
JP2005247752A (en) * 2004-03-04 2005-09-15 Hokuren Federation Of Agricult Coop:The Blood cholesterol rise inhibitor
JP4669235B2 (en) * 2004-04-21 2011-04-13 ホクレン農業協同組合連合会 Bifidobacteria growth agent in intestinal environment
JP4162147B2 (en) * 2005-04-21 2008-10-08 ホクレン農業協同組合連合会 Allergy suppressant
CA2628035A1 (en) * 2005-10-13 2007-04-19 Meiji Seika Kaisha, Ltd. Composition for improving intestinal microflora
JP5921894B2 (en) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 Intestinal butyric acid producing bacteria increasing agent

Also Published As

Publication number Publication date
EP3431089A4 (en) 2020-04-15
JPWO2017159643A1 (en) 2018-03-22
US20190091248A1 (en) 2019-03-28
CN109069522A (en) 2018-12-21
EP3431089A1 (en) 2019-01-23
WO2017159643A1 (en) 2017-09-21
KR20180122379A (en) 2018-11-12
PH12018501988A1 (en) 2019-06-24
JP6275931B1 (en) 2018-02-07

Similar Documents

Publication Publication Date Title
SG11201807500RA (en) Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2021000609A (en) Methods of treatment with cyp3a4 substrate drugs.
WO2018093238A3 (en) Composition comprising as active ingredient strain having excellent ability to produce formic acid for preventing or treating obesity or metabolic syndromes caused by obesity
MX2017015012A (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
BR112015018549A8 (en) iron deficiency treatment methods
WO2015035410A8 (en) Cancer therapy
MX2021003006A (en) Bacteriotherapy against proprionibacterium acnes for the treatment of acne.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
PH12018501989A1 (en) Proliferative agent for faecalibacterium
WO2018093237A3 (en) Composition comprising formic acid or pharmaceutically acceptable salt thereof as active ingredient for preventing or treating obesity or metabolic syndromes caused by obesity
MX2020001768A (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel.
WO2018074862A3 (en) Pharmaceutical composition comprising tha as active ingredient for treating breast cancer
BR112018008108A2 (en) preservation of water soluble vitamins
MX2020007222A (en) Minocycline for treating inflammatory skin conditions.
MX2022013681A (en) Methods and compositions for treatment of hypercalciuria and nephrolithiasis.
MX2023005014A (en) Methods of treating chronic inflammatory diseases.
GB2550750A (en) Anthelmintic compounds
PH12015502351A1 (en) Herbal compositions for treating pain and skin disorders
BR112018002433A2 (en) pharmaceutical composition for migraine treatment
WO2019125077A3 (en) Composition for preventing or treating ischemic diseases comprising cuscuta japonica extract as active ingredient
EA201990676A1 (en) OSTEOARTHRITIS TREATMENT
MX2020006351A (en) Method of providing celiprolol therapy to a patient.
MX2021012580A (en) Multiparticulate l-carnitine and nootropic compositions and related methods.